Training activity information
Details
Analyse, interpret and draft a clinical report for appropriate assays for suspected/confirmed plasma cell dyscrasias
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What does success look like?
- Identify what is expected of you in relation to analysing, interpreting, and drafting reports for assays related to plasma cell dyscrasias.
- Consider how the learning outcomes apply, specifically in relation to report preparation, interpreting somatic variants, clonality, and interacting with relevant specialties for diagnosis and management.
- Discuss with your training officer to gain clarity of what is expected of you in relation to expectations for integrating results from multiple assay types (e.g., FISH, molecular) into a unified report.
What is your prior experience of this activity?
- Think about your knowledge of specific assays used for plasma cell dyscrasias and prior experience with interpreting their results (e.g., flow cytometry, FISH).
- Consider possible challenges you might face during the activity, such as interpreting complex genetic findings (e.g., IgH rearrangements by FISH) or drafting a clinically relevant report that integrates different technical findings.
- Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example if interpretation of results requires integrating data from technical platforms unfamiliar to you or when assessing risk stratification based on complex FISH findings.
- Acknowledge how you feel about the responsibility of reporting findings that guide risk stratification and management for these disorders.
What do you anticipate you will learn from the experience?
- Consider the specific skills you want to develop, such as systematically integrating results from molecular assays (e.g., NGS, FISH) for a coherent diagnosis of plasma cell dyscrasias.
- Identify the specific insights you hope to gain into linking genomic findings (e.g., high-risk translocations) to patient risk stratification and management.
What additional considerations do you need to make?
- Consult actions identified following previous experiences of drafting clinical reports for haematological malignancies.
- Identify important information you need to consider before embarking on the activity, such as the patient’s detailed clinical history and results from relevant non-molecular tests (e.g., serum protein electrophoresis) to inform interpretation.
In action
Is anything unexpected occurring?
- Are you noticing anything surprising or different from what you anticipate whilst analysing the data and interpreting the results for plasma cell dyscrasias (PCDs)?
- Are you encountering situations such as:
- Complex electrophoretic patterns or unusual molecular data that require conscious effort to interpret?
- A discrepancy arising when integrating findings from different assays (e.g., FISH and molecular data)?
- Ambiguous findings or unexpected data requiring external expertise?
How are you reacting to the unexpected development?
- How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your analytical methodology by immediately consulting external reference materials or seeking additional resources?
- Consider the steps you are taking in the moment, such as immediately deciding how to integrate conflicting molecular and electrophoretic data to word the interpretation accurately.
- How are you feeling in that moment? For instance, are you finding it difficult to ensure the clinical report meets SIHMDS compliance criteria or interpret the clinical significance of a rare translocation? Is it affecting your confidence in contributing effectively to the final diagnosis?
What is the conclusion or outcome?
- Identify how you are working within your scope of practice. For example, are you successfully integrating findings from multiple assays to arrive at a coherent, justified diagnostic conclusion? Or are you needing support because complex PCD findings or ambiguities require the pathological verification of a senior scientist or clinician?
- What are you learning as a result of the unexpected development? For example, are you gaining insight into the criticality of integrating molecular, cytogenetic, and electrophoretic findings for accurate PCD classification?
On action
What happened?
- Begin by summarising the key steps you took when analysing the assay results and drafting the clinical report for the plasma cell dyscrasia case(s).
- Consider specific events, actions, or interactions which felt important, such as how you analysed the key assay results (e.g., protein electrophoresis, flow cytometry, molecular/cytogenetic findings, histopathology) and how you ensured the essential elements were included in the draft report for classification.
- Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately consulting international guidelines when faced with ambiguous findings to confirm the classification of the plasma cell dyscrasia.
- How did you feel during this experience, e.g., did you feel focused on accurate data integration or challenged by the necessity of integrating different types of data (e.g., serum markers and molecular findings) into a unified interpretation?
How has this experience contributed to your developing practice?
- Identify what learning you can take from this experience regarding analysis and reporting for PCDs. What strengths did you demonstrate, e.g., skill in drafting a clinical report that successfully integrates various assay results?
- What skills and/or knowledge gaps were evident, e.g., difficulty with precise descriptive terminology for a specific molecular finding in a PCD subtype?
- Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in your ability to analyse and interpret appropriate assays for plasma cell dyscrasias and prepare interpretive reports for common haematological malignancies?
- Identify any challenges you experienced, such as needing to seek advice or clarification on scope of practice regarding the exact pathological classification required in the final report based on borderline findings, and how you reacted to this.
What will you take from the experience moving forward?
- Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to refining your reporting skills for these conditions.
- What will you do differently next time you approach report drafting, for instance, by proactively consulting reporting templates and terminology guides to ensure all essential elements are included and accurately phrased?
- Do you need to practise any aspect of the activity further, such as integrating different types of data (e.g., cytogenetic, molecular, protein) or reviewing international guidelines for classifying plasma cell dyscrasias?
Beyond action
Have you revisited the experiences?
- How have your subsequent experiences of analysing and reporting molecular and cytogenetic data for plasma cell dyscrasias (PCDs) since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how an instance where a subsequent PCD case required complex integration of FISH, flow, and molecular data for risk stratification forced you to re-evaluate the detail and clarity of your initial data integration protocol you applied during your first attempt at this training activity?
- Considering what you understand about reporting standards and complex data integration now, were the actions or considerations you identified after your initial reflection on this training activity sufficient? How have you since implemented or adapted improvements in your report drafting methodology based on further learning and experiences? For example, how you proactively reviewed and integrated standardised reporting templates for high-risk translocations specific to multiple myeloma to ensure consistency and clarity in risk stratification reporting?
- Has discussing ambiguous PCD reports or cases of conflicting multi-assay results or the impact of imprecise reporting on patient management with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior colleague about a report where subtle cytogenetic findings were missed, impacting risk assessment refined your understanding of the critical nature of meticulous multi-assay correlation during interpretation?
How have these experiences impacted upon current practice?
- How has the learning from this initial training activity, in combination with subsequent experiences, contributed to your overall confidence and skill in analysing, interpreting, and drafting PCD reports, particularly in preparing for assessments like producing diagnostic clinical reports? For example, how your accumulated ability in integrating complex molecular and cytogenetic data now enables you to confidently produce a clinically robust report for plasma cell dyscrasia findings during an assessment?
- How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to PCD reporting? How does this evolved understanding help you identify when something is beyond your scope of practice or requires escalation? For example, how your evolved approach means you now routinely seek advice immediately when interpretation requires prognostic assessment based on novel or rare genetic markers not covered in routine guidelines?
- Looking holistically at your training journey, how has this initial reporting experience, revisited with your current perspective, contributed to your development in generating factual reports and understanding patient management implications for plasma cell dyscrasias?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 4 |
Outcome
Analyse, interpret and prepare interpretive reports for common haematological malignancies, including results for somatic variants, clonality, and somatic hypermutation. |
| # 5 |
Outcome
Interpret the associated IQC and EQA of the laboratory tests for investigation of haematological malignancies. |
| # 6 |
Outcome
Practice with the relevant specialties for the diagnosis, monitoring and management of haematological malignancies. |